Long-Term Use of Metformin Is Associated With Reduced Risk of Cognitive Impairment With Alleviation of Cerebral Small Vessel Disease Burden in Patients With Type 2 Diabetes

Zhenjie Teng1,2, Jing Feng3, Qianqian Qi1,2, Yanhong Dong2, Yining Xiao1,2, Xiaohua Xie2, Nan Meng2, Huifang Chen2, Wenhui Zhang4 and Peiyuan Lv1,2*

1 Department of Neurology, Hebei Medical University, Shijiazhuang, China, 2 Department of Neurology, Hebei General Hospital, Shijiazhuang, China, 3 Department of Endocrinology, Hebei General Hospital, Shijiazhuang, China, 4 Memory Clinic, Hebei General Hospital, Shijiazhuang, China

Objective: Type 2 diabetes (T2D) is a risk factor for cognitive impairment and cerebral small vessel disease (CSVD). The relation of metformin use and cognitive impairment or CSVD is not clear. The objective of this study was to investigate the cross-sectional effects of long-term use of metformin on total CSVD burden and cognitive function in patients with T2D.

Methods: A total of 234 participants with T2D from the memory clinic in Hebei General Hospital were enrolled in this retrospective study. Duration of metformin use and dosage were recorded. Along with cerebral magnetic resonance imaging (MRI) examination, Mini-Mental State Examination (MMSE) was also performed to assess their cognitive status. We determined the validated total CSVD score (ranging from 0–4) by combining four markers of CSVD that were visually rated. We used binary logistic regression analysis, ordinal logistic regression analysis and mediation analysis to assess the relation of long-term use of metformin with CSVD burden and cognitive function.

Results: Binary logistic regression analysis showed long-term use of metformin was associated with reducing the risk of cognitive impairment (OR: 0.446; 95% Confidence Interval (CI): 0.249 to 0.800; P = 0.007), after adjustment of potential confounders, such as total CSVD burden score, age, HbA1c, hypertension, history of stroke, homocysteine, body mass index, TG and HDL-C. Ordinal logistic regression analysis suggested that long-term use of metformin was associated with alleviation of total CSVD burden score (OR: 0.583; 95% CI: 0.359 to 0.943; P = 0.027), after adjusting for age, HbA1c, hypertension, history of stroke, homocysteine, body mass index, TG and HDL-C. Mediation analysis showed significant mediation by the presence of severe CSVD burden score for long-term use of metformin in relation to cognitive impairment.
INTRODUCTION

Cognitive impairment is a growing problem, which can range in severity from mild cognitive impairment to dementia. Due to an increase in population aging and growth, the number of people with cognitive impairment is rising, which imposes a tremendous burden on families and society (GBD 2016 Dementia Collaborators, 2019; Hamilton et al., 2021).

Cerebral small vessel disease (CSVD) is a primary cause of cognitive impairment in the elderly and it accounts for about 50% of dementias worldwide (Wardlaw et al., 2019; Zlokovic et al., 2020). CSVD describes pathological processes affecting the small arteries, arterioles, capillaries and small veins of the brain. Signs of CSVD on conventional magnetic resonance imaging (MRI) include white matter hyperintensities (WMH), lacune of presumed vascular origin, cerebral microbleeds (CMBs), brain atrophy, microinfarcts and enlarged perivascular spaces (EPVS) (Wardlaw et al., 2013). CSVD is a dynamic, whole-brain disorder. CSVD burden score, combined the individual markers into one score, can reflect the overall burden and be more representative of CSVD (Staals et al., 2014). Recent studies have revealed that blood-brain barrier (BBB) dysfunction and endothelial cell dysfunction seem to be pivotal factors contributing to the pathogenesis of CSVD (Ihara and Yamamoto, 2016; Wardlaw et al., 2019). Factors, such as oxidative stress, inflammation, hypoxia, and hypoperfusion may lead to BBB and endothelial dysfunction (Grochowski et al., 2018; Low et al., 2019; Zanon et al., 2021), which is worse in patients with cognitive impairment (Nation et al., 2019).

Type 2 diabetes (T2D) is also an important risk factor for cognitive impairment, which in turn can impair self-management of T2D (Xue et al., 2019; Launer, 2020). Metformin, a biguanide derivative, broadly used for treating T2D, has caught considerable attention among researchers because of its ability to improve cognitive function in patients with T2D (Zhang et al., 2020; Gorgich et al., 2021; Kodali et al., 2021). The mechanisms include ameliorating oxidative stress, inhibiting inflammation, mediating nutrient-sensing pathway and enhancing autophagy, although the relationships among these mechanisms are complex and not yet fully understood (Gorgich et al., 2021; Hu et al., 2021; Kodali et al., 2021). However, some studies have implied that metformin may increase the risk of cognitive impairment in patients with T2D (Moore et al., 2013; Porter et al., 2019).

To the best of our knowledge, few studies have investigated the relationship between CSVD burden and metformin use, although metformin could act on some of the mechanisms that lead to CSVD. Collectively, the present study aims to analyze the relation of long-term use of metformin with CSVD burden and cognitive function in patients with T2D.

MATERIALS AND METHODS

Participants

This is a case-control study of patients with T2D from the memory clinic in Hebei General Hospital. From January 2017 to January 2019, a total of 234 patients with a diagnosis of T2D who underwent complete MRI sequences necessary for evaluating CSVD markers were included. Inclusion criteria for all participants were able to undergo cognitive testing and independent in daily life. We excluded those with any contraindication to MRI, history of T2D <6 years, acute stroke or other neurologic disorders (epilepsy, trauma, malignancy, schizophrenia, central nervous system demyelinating diseases, or depressive disorder), other diseases, such as hyperthyroidism, hypothyroidism, severe hepatorenal dysfunction, hematological diseases and carbon monoxide poisoning.

Clinical Assessment

In this study, the following variables were collected: demographic profiles (age, gender, years of education, height, weight), medical history (hypertension, T2D, coronary heart disease, stroke and intracranial hemorrhage), cigarette smoking and alcohol drinking status and the use of medications. Laboratory markers such as fasting plasma glucose (FPG), hemoglobin A1c (HbA1c), total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), very low density lipoprotein cholesterol (VLDL-C), homocysteine and Uric Acid were recorded.

Metformin Use

All medications, duration of use, and dosage were recorded, which included the ascertainment of metformin usage. Participants were classified into the two groups by duration of metformin usage: (i) duration of metformin use as 6 or less years; and (ii) duration of metformin use as more than 6 years (Ng et al., 2014).

Magnetic Resonance Imaging Data Acquisition, Interpretation, and Evaluation

Magnetic resonance imaging examination was performed in all patients using 3.0 tesla MR scanners (Signa, GE Healthcare of American). The standardized neuroimaging protocol included T1-weighted imaging (T1WI), T2-weighted imaging (T2WI), fluid-attenuated inversion recovery (FLAIR) and susceptibility weighted imaging (SWI). MR scanning parameters: T1WI: repetition time (TR)/echo time (TE) = 1,909/20.2 milliseconds (ms), slice thickness = 5 mm; T2WI: TR/TE = 5,000/125 ms,

Conclusion: Long-term use of metformin was associated with lower rates of cognitive impairment and lower total CSVD burden score in patients with T2D. A proportion of the relation between long-term use of metformin and cognitive impairment may be attributable to alleviation of CSVD burden.

Keywords: metformin, cerebral small vessel disease, cognitive impairment, diabetes, relationship
Cerebral Small Vessel Disease Burden

Long-Term Use of Metformin and Total Cerebral Small Vessel Disease Burden Score

RESULTS

Participants Characteristics

This study included 234 patients with T2D. Mean age of the study participants was 67.8 ± 8.9 years and 53.8% (n = 126) were male. All individuals were divided into cognitive impairment (CI) (n = 101) group and no cognitive impairment (NCI) (n = 133) group according to cognitive function assessment. Characteristics of the study participants between CI and NCI group are shown in **Table 1**. The participants in the CI group were significantly older and more likely to have a history of stroke than those in the NCI group. The CI group presented higher HbA1c and homocysteine levels, but shorter duration of metformin use than NCI group. In addition, the total CSVD burden score was higher in subjects with CI.

**Long-Term Use of Metformin and Cognitive Impairment**

The proportion of participants with metformin use of >6 years was significantly lower in CI group than NCI group (P = 0.001) (**Table 1**). In unadjusted binary logistic regression, long-term use of metformin was associated with reducing the risk of cognitive impairment (OR: 0.410; 95% Confidence Interval: 0.240 to 0.700; P = 0.001). The association remained significant (OR: 0.446; 95% Confidence Interval (CI): 0.249 to 0.800; P = 0.007), after further adjustment for potential confounders, such as total CSVD burden score, age, HbA1c, hypertension, history of stroke, homocysteine, body mass index, TG and HDL-C (**Figure 1**).

**Long-Term Use of Metformin and Total Cerebral Small Vessel Disease Burden Score**

In unadjusted ordinal logistic regression analysis, long-term use of metformin was associated with alleviation of total CSVD burden score (OR: 0.511; 95% Confidence Interval: 0.322 to 0.708; P = 0.004). This trend remained statistically significant (OR: 0.583; 95% Confidence Interval: 0.359 to 0.943; P = 0.027),...
26.9% of the total effect was attributable to mediation by and body mass index (Figure 3). In the relation between long-term use of metformin and cognitive impairment, 26.9% of the total effect was attributable to mediation by the presence of severe CSVD burden score ($P = 0.04$). Conclusions did not change when the possible interaction between long-term use of metformin and CSVD burden score was taken into account.

**DISCUSSION**

In this cross-sectional study, we investigated the association of long-term use of metformin with total CSVD burden and cognitive function in patients with T2D. To our knowledge, this is the first study exploring the association between long-term use of metformin and total CSVD burden. We found that long-term use of metformin was a protective factor for total CSVD burden and cognitive impairment after controlling for several confounders. Moreover, the presence of severe CSVD burden score was a significant mediator in the relation between long-term use of metformin and cognitive impairment. Furthermore, although no temporal relations can be derived from this cross-sectional study, mediation analysis supports the hypothesis that long-term use of metformin may alleviate the total CSVD burden, which, in turn, may reduce the risk of cognitive impairment.

Compared to previous studies, an important strength of our study was the assessment of the relationship between CSVD burden and metformin use in patients with T2D. In our study, long-term use of metformin was associated with lower total CSVD burden score, which suggested that long-term use of metformin may delay the progression of CSVD. The current study adds to the literature supporting that metformin may have a neuroprotective effect. Although the mechanism remains elusive, several possible mechanisms may explain this effect. One possible mechanism of metformin induced protection in CSVD is chronic activation of AMP-activated protein kinase (AMPK), which plays important roles in regulation of energy metabolism (Steinberg and Carling, 2019; Crunkhorn, 2021). AMPK is highly expressed in neurons, neuroglia and astrocytes of the neurogliovascular unit. Interestingly, several of the cellular and functional constituents of the neurogliovascular unit represent possible entry points for disease mechanisms in CSVD (Wardlaw et al., 2019). Increasing evidence is showing that AMPK activation alleviates the damage of BBB and improves endothelial functions (Zhao et al., 2014; Prasad et al., 2017; Wang et al., 2017; Wu et al., 2020), which were key factors contributing to the pathogenesis of CSVD (Wardlaw et al., 2019). As a well-recognized AMPK activator, a previous study of experimental animal models found that metformin could inhibit inflammation, thereby alleviating endothelial injury and lowering BBB permeability by an AMPK-dependent intercellular adhesion molecule-1 (ICAM-1) down-regulation (Liu et al., 2014). Additionally, lines of evidence suggested AMPK activation plays a key role of metformin in improving endothelial functions (Salvatore et al., 2020). Besides, chronic metformin treatment could enhance angiogenesis by AMPK signaling and then offer potent neuroprotective effects (Venna et al., 2014). Other possible mechanisms, such as ameliorating oxidative stress (Zeng et al., 2019), inhibiting inflammation (Jin et al., 2014)

**TABLE 1 | Characteristics of the study participants between CI and NCI group.**

| Variable                          | CI group (n = 101) | NCI group (n = 133) | P value |
|-----------------------------------|-------------------|---------------------|---------|
| Age (mean, SD), year              | 70.2 ± 8.4        | 66.0 ± 8.9          | <0.001  |
| Sex (male), n (%)                 | 57 (56.4)         | 69 (51.9)           | 0.489   |
| Body mass index, mean (SD), kg/m² | 24.8 ± 9.6        | 25.4 ± 3.4          | 0.123   |
| Current smoking, n (%)            | 39 (38.6)         | 45 (33.8)           | 0.450   |
| Alcohol use, n (%)                | 26 (25.7)         | 44 (33.1)           | 0.225   |
| Hypertension, n (%)               | 80 (79.2)         | 94 (70.7)           | 0.139   |
| Coronary heart disease, n (%)     | 30 (29.7)         | 47 (35.3)           | 0.364   |
| History of stroke                 | 55 (54.5)         | 43 (32.3)           | 0.001   |
| Duration of T2D, median (IQR), year | 10 (7–17)       | 10 (8–14)           | 0.462   |
| FPG, median (IQR), mmol/L         | 7.17 (5.76–9.42)  | 6.95 (5.86–8.46)    | 0.831   |
| HbA1c, median (IQR), %            | 7.40 (6.70–8.19)  | 7.00 (6.40–7.85)    | 0.023   |
| Metformin use (>6 years), n (%)   | 35 (34.7)         | 75 (56.4)           | 0.001   |
| Other anti-diabetic drugs         | 31 (30.7)         | 44 (33.1)           | 0.698   |
| Glitazones, n (%)                 | 25 (24.8)         | 37 (27.8)           | 0.598   |
| Sulfonylureas, n (%)              | 42 (41.8)         | 65 (48.9)           | 0.268   |
| Insulin, n (%)                    | 55 (54.5)         | 62 (46.6)           | 0.235   |
| TC, median (IQR), mmol/L          | 4.45 (3.56–5.21)  | 4.25 (3.60–5.27)    | 0.898   |
| TG, median (IQR), mmol/L          | 1.61 (1.12–2.16)  | 1.33 (1.08–2.09)    | 0.124   |
| HDL-C, median (IQR), mmol/L       | 1.04 (0.87–1.22)  | 1.06 (0.90–1.28)    | 0.148   |
| LDL-C, median (IQR), mmol/L       | 2.75 (2.02–3.45)  | 2.69 (2.20–3.52)    | 0.860   |
| VLDL-C, median (IQR), mmol/L      | 0.45 (0.29–0.67)  | 0.45 (0.31–0.63)    | 0.759   |
| Uric Acid, median (IQR), umol/L   | 305 (234–378)     | 290 (253–355)       | 0.932   |
| Homocysteine, median (IQR), umol/L| 15.5 (12.9–19.2)  | 14.2 (11.6–16.2)    | <0.001  |
| Total CSVD burden score           |                  |                     | <0.001  |

Bold values indicates $P < 0.05$. CI, cognitive impairment; NCI, no cognitive impairment; SD, standard deviation; IQR, interquartile range; FPG, fasting plasma glucose; HbA1c, hemoglobin A1c; TC, total cholesterol; TG, triglyceride; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; VLDL-C, very low density lipoprotein cholesterol.

after adjusting for age, HbA1c, hypertension, history of stroke, homocysteine, body mass index, TG and HDL-C (Figure 2).

**Mediation by Severe Cerebral Small Vessel Disease Burden Score**

Mediation analysis showed significant mediation by the presence of severe CSVD burden score for long-term use of metformin in relation to cognitive impairment after controlling the regression analyses for age, hypertension, history of stroke and body mass index (Figure 3). In the relation between long-term use of metformin and cognitive impairment, 26.9% of the total effect was attributable to mediation by the presence of severe CSVD burden score ($P = 0.04$). Conclusions did not change when the possible interaction between long-term use of metformin and CSVD burden score was taken into account.
or other neuroprotective mechanisms may some also partly explain that metformin may delay the progression of CSVD (Grochowski et al., 2018; Wardlaw et al., 2019). Therefore, these above mechanisms may plausibly explain the result in our study that long-term use of metformin was associated with alleviation of total CSVD burden.
Previous studies have mainly focused on the association between metformin use and cognitive impairment. A meta-analysis, including 10 studies, suggested that metformin use significantly reduced the occurrence of cognitive impairment in patients with T2D (Zhang et al., 2020). Similarly, two recent animal studies also found metformin can improve cognitive function (Gorgich et al., 2021; Kodali et al., 2021). Whereas, Porter et al. (2019) reported that metformin use of older adults was associated with an increased risk (34 to 36%) of cognitive impairment. In addition, the Diabetes Prevention Program Outcomes Study (DPPOS) found that exposure to metformin was not related to cognition (Luchsinger et al., 2017). The discrepancy may be attributable to duration of metformin usage and T2D, education levels, economic differences and other related confounders. Consistent with our findings, a prospective observational study conducted by Samaras et al. (2020) confirmed that metformin use over 6 years in older people with T2D was related with lesser decline in global cognition and executive function and lower dementia risk compared with those not receiving metformin. However, CSVD, as an important cause of cognitive impairment, should be taken into account when explored the relationship between metformin use and cognitive impairment in researches, yet few do. In our study, after controlling for total CSVD burden score and other confounders, we still found metformin use over 6 years was associated with reducing the risk of cognitive impairment. Furthermore, our result suggest that a proportion of the association may be attributable to alleviation of CSVD burden after controlling the regression analyses for age, hypertension, history of stroke and body mass index in mediation analysis.

Our study has some limitations. Firstly, the cross-sectional design allows the investigation of only associations. Secondly, the study was conducted in one center with a relatively small sample size and the generate sampling bias can not be excluded. However, the study assessed four markers of CSVD instead of focusing on one or two. Thirdly, metformin usage and duration of its usage were recorded by self-reports of participants instead of medical records. Furthermore, MMSE is a measure of global cognitive function. Therefore, our research could not explore the effects of metformin on specific cognitive domains. Finally, some other potential confounders, such as diabetes severity, were not taken into account and may bias our analyses. Future large longitudinal studies will be needed to address these issues.

CONCLUSION

In conclusion, long-term use of metformin was associated with lower rates of cognitive impairment and lower total CSVD burden score in patients with T2D. We demonstrated the likelihood of the protection by metformin on cognitive function and CSVD. More importantly, a proportion of the beneficial effects of long-term use of metformin on cognitive function may be attributable to alleviation of CSVD burden. Therefore, we believe metformin has the potential to be useful in the clinical treatment of cognitive impairment and CSVD. To fully assess the mechanisms of beneficial effects of metformin on cognitive function and CSVD, future longitudinal and randomized studies are needed.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Ethical Committee of Hebei General Hospital. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

AUTHOR CONTRIBUTIONS

PL designed the study protocol and revised the manuscript. ZT and JF wrote the manuscript. YD and HC contributed to acquisition and interpretation of data. QQ, YX, XX, NM, and WZ made substantial contributions to data acquisition and analysis. All authors contributed to the article and approved the submitted version.

REFERENCES

Crunkhorn, S. (2021). A new route to regulating AMPK activity. Nat. Rev. Drug Discov. 20, 175. doi: 10.1038/s41573-021-00021-x
Doubl, F. N., MacLullich, A. M., Ferguson, K. J., Dennis, M. S., and Wardlaw, J. M. (2010). Enlarged perivascular spaces on MRI are a feature of cerebral small vessel disease. Stroke 41, 450–454. doi: 10.1161/STROKEAHA.109.564914
Fazekas, F., Kleinert, R., Offenbacher, H., Schmidt, R., Kleinert, G., and Payer, F. (1993). Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology 43, 1683–1689. doi: 10.1212/WNL.43.9.1683
GBD 2016 Dementia Collaborators (2019). Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 18, 88–106. doi: 10.1016/S1474-4422(18)30403-4
Gorgich, E., Parsaie, H., Yarmand, S., Baharvand, F., and Sarbishegi, M. (2021). Long-term administration of metformin ameliorates age-dependent oxidative stress and cognitive function in rats. Behav. Brain Res. 410:113343. doi: 10.1016/j.bbr.2021.113343
Gregoire, S. M., Chaudhary, U. J., Brown, M. M., Yousry, T. A., Kallis, C., Jager, H. R., et al. (2009). The Microbleed Anatomical Rating Scale (MARS): reliability of a tool to map brain microbleeds. Neurology 73, 1759–1766. doi: 10.1212/WNL.0b013e3181c3a47d
Grocowski, C., Litak, J., Kamieniak, P., and Maciejewski, R. (2018). Oxidative stress in cerebral small vessel disease. Role of reactive species. Free Radic. Res. 52, 1–13. doi: 10.1080/10715762.2017.1402304
Hamilton, O., Backhouse, E. V., Janssen, E., Jochems, A., Maher, C., Ritakari, T. E., et al. (2021). Cognitive impairment in sporadic cerebral small vessel disease:
a systematic review and meta-analysis. *Alzheimers Dement.* 17, 665–685. doi: 10.1002/alz.12221

Hu, D., Xie, F., Xiao, Y., Lu, C., Zhong, J., Huang, D., et al. (2021). Metformin: a Potential Candidate for Targeting Aging Mechanisms. *Aging Dis.* 12, 480–493. doi: 10.14336/AD.2020.0702

Ihara, M., and Yamamoto, Y. (2016). Emerging Evidence for Pathogenesis of Sporadic Cerebral Small Vessel Disease. *Stroke* 47, 554–560. doi: 10.1161/STROKEAHA.115.009627

Jiang, Y., Wang, Y., Yuan, Z., Xu, K., Zhang, K., Zhu, Z., et al. (2019). Total MRI load of cerebral small vessel disease and cognitive ability in older people. *Neurobiol. Aging* 36, 2806–2811. doi: 10.1016/j.neurobiolaging.2015.06.024

Staals, J., Makin, S. D., Doubal, F. N., Dennis, M. S., and Wardlaw, J. M. (2014). Stroke subtype, vascular risk factors, and total MRI brain small-vessel disease burden. *Neurology* 83, 1228–1234. doi: 10.1212/WNLI.0000000000008837

Strebberg, G. R., and Carling, D. (2019). AMP-activated protein kinase: the current landscape for drug development. *Nat. Rev. Drug Discov.* 18, 527–551. doi: 10.1038/s41573-019-0019-2

Venna, V. R., Li, J., Hammond, M. D., Mancini, N. S., and McCullough, L. D. (2014). Chronic metformin treatment improves post-stroke angiogenesis and recovery after experimental stroke. *Eur. J. Neurosci.* 39, 2129–2138. doi: 10.1111/ejn.12556

Wang, X., Xue, G. X., Liu, W. C., Shu, H., Wang, M., Sun, Y., et al. (2017). Melatonin alleviates lipopolysaccharide-compromised integrity of blood-brain barrier through activating AMP-activated protein kinase in old mice. *Aging Cell.* 16, 414–421. doi: 10.1111/ace.12572

Wardlaw, J. M., Smith, C., and Dichgans, M. (2019). Small vessel disease: mechanisms and clinical implications. *Lancet Neurol.* 18, 684–696. doi: 10.1016/S1474-4422(19)30079-1

Wardlaw, J. M., Smith, E. E., Biessels, G. J., Cordonnier, C., Fazekas, F., Frayne, R., et al. (2013). Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. *Lancet Neurol.* 12, 822–838. doi: 10.1016/S1474-4422(13)70248-8

Wu, J., Zhao, Y., Fan, Z., Chen, Q., Chen, J., Sun, Y., et al. (2020). Soluble epoxide hydrolase inhibitor protects against blood-brain barrier dysfunction in a mouse model of type 2 diabetes via the AMPK/HO-1 pathway. *Biochem. Biophys. Res. Commun.* 524, 354–359. doi: 10.1016/j.bbrc.2020.01.085

Xue, M., Xu, W., Ou, Y. N., Cao, X. P., Tan, M. S., Tan, L., et al. (2019). Diabetes mellitus and risks of cognitive impairment and dementia: a systematic review and meta-analysis of 144 prospective studies. *Aging Res. Rev.* 55,100944. doi: 10.1016/j.arr.2019.100944

Zanón, Z. M., Sveikata, L., Viswanathan, A., and Yilmaz, P. (2021). Cerebral small vessel disease and vascular cognitive impairment: from diagnosis to management. *Curr. Opin. Neurol.* 34, 246–257. doi: 10.1097/WCO.0000000000000913

Zeng, J., Zhu, L., Liu, J., Zhu, T., Xie, Z., Sun, X., et al. (2019). Metformin Protects against Oxidative Stress Injury Induced by Ischemia/Reperfusion via Regulation of the InoNcRNA-H1/H11mr-148a-3p/Rock2 Axis. *Oxid. Med. Cell. Longev.* 2019,8768327. doi: 10.1155/2019/8768327

Zhang, Q. Q., Li, W. S., Liu, Z., Zhang, H. L., Ba, Y. G., Zhang, R. X., et al. (2020). Metformin therapy and cognitive dysfunction in patients with type 2 diabetes: a meta-analysis and systematic review. *Medicine* 99:e19378. doi: 10.1097/MD.0000000000019378

Zhao, Z., Hu, J., Gao, X., Liang, H., and Liu, Z. (2014). Activation of AMPK attenuates lipopolysaccharide-impaired integrity and function of blood-brain barrier in human brain microvascular endothelial cells. *Exp. Mol. Pathol.* 97, 386–392. doi: 10.1016/j.yexmp.2014.09.006

Zlokovic, B. V., Gottesman, R. F., Bernstein, K. E., Seshadri, S., McKee, A., Snyder, H., et al. (2020). Vascular contributions to cognitive impairment and dementia (VCIID): a report from the 2018 National Heart, Lung, and Blood Institute and National Institute of Neurological Disorders and Stroke Workshop. *Alzheimers Dement.* 16, 1714–1733. doi: 10.1002/alz.12157

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Teng, Feng, Qi, Dong, Xiao, Xue, Meng, Chen, Zhang and Lv. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the terms and conditions of the Creative Commons Attribution License (CC BY) are complied with.